United Kingdom

UK: NHS to Offer Wegovy to 1.2M Heart Patients

Is Wegovy a life-saving breakthrough for heart disease or an expensive distraction from lasting lifestyle solutions?

Published APR 1

UK: NHS to Offer Wegovy to 1.2M Heart Patients

Story

Above: A person injecting Wegovy in Sydney, Australia, on Nov. 17, 2024. Image credit: Steve Christo/Corbis/Getty Images

The Facts

The NHS in England will offer semaglutide in the form of Novo Nordisk's Wegovy to around 1.2 million people in the country with cardiovascular disease to reduce their risk of heart attacks and strokes.
NHS England
Independent
The Telegraph
The development follows guidance published by the National Institute for Health and Care Excellence (NICE) approving the weekly injection of the drug for adults with a Body Mass Index (BMI) of 27 or above who have previously had a heart attack, stroke or peripheral arterial disease.
Nice
Nice
NICE made the recommendation after clinical data from the "SELECT" trial, which enrolled 17,604 people, found that semaglutide reduced the risk of a major cardiovascular event — such as a heart attack, stroke or cardiovascular death — by 20% compared with a placebo.
Nice
The study also discovered that the cardiovascular benefit of semaglutide appeared early in patients, before significant weight loss occurred, which NICE claimed suggested there was an independent "mechanism of action" at work, directly on the heart and blood vessels.
Nice
Daily Mail
guardian
The NHS will prescribe the weight-loss drug as a treatment option alongside its standard care, which includes other medications and lifestyle changes, such as a healthier diet, greater physical activity, stopping smoking and reducing alcohol intake.
NHS England
Nice
In a statement, Health Minister Sharon Hodgson claimed that extending the drug's use to people with cardiovascular disease would act as a "life saver," with the NHS expecting to begin rolling out the jabs within months.
NHS England

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

Wegovy is a genuine breakthrough for the 1.2 million people in England living with cardiovascular disease, which will cut their risk of a heart attack and stroke by 20%, as the SELECT trial has already proved. As a result, expanding NHS access to semaglutide is a cost-effective decision that will save lives when used with existing treatment options.

Nice

NHS England

Narrative B

While semaglutide has its uses, it's crucial to remember that drugs like Wegovy are not magic bullets and lack long-term supporting data. Treating health conditions through expensive weekly injections ignores the root causes driving these ailments and risks sidelining the importance of lifestyle changes that are proven to deliver lasting results.

NPR